3 Oleochemical Additives Maker, Contract Drug Development and Manufacturing Company and Generic Drug Maker Stocks With a Strong Future Roadmap: Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals

Oleochemical, contract pharma and generic stocks let investors follow companies that serve a growing part of the Indian economy. Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals cover an oleochemical additives maker, a contract drug development and manufacturing company and a generic drug maker.

This list covers three oleochemical, contract pharma and generic stocks with complete current figures: Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Oleochemical, Contract Pharma and Generic Stocks?

Oleochemical, contract pharma and generic stocks are listed companies that make additives for food, plastics and cosmetics, serve global pharma and biotech firms with discovery, development and manufacturing and sell generics, branded medicines and active ingredients. Their earnings depend on orders, approvals and product mix.

Oleochemical, Contract Pharma and Generic Stocks at a Glance

On valuation, Alembic Pharmaceuticals trades at a P/E below the industry P/E, while Fine Organic Industries and Anthem Biosciences trade above it, which reflects the growth the market already expects. Readers comparing oleochemical, contract pharma and generic stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Oleochemical, Contract Pharma and Generic Stocks Have a Strong Roadmap in India?

Oleochemical, contract pharma and generic stocks have a strong roadmap in India because global drug makers outsourcing more work, wider use of specialty additives and steady medicine demand keep widening the market for these specialty companies.

• Outsourcing. Global pharma partners with Indian developers.
• Specialty additives. Niche products support pricing strength.
• Generic demand. Medicines bring repeat orders.

Why Fine Organic Industries Features Among These Oleochemical, Contract Pharma and Generic Stocks

Among the oleochemical, contract pharma and generic stocks on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.

In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%.

Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.

Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.

Why Anthem Biosciences Features Among These Oleochemical, Contract Pharma and Generic Stocks

Among the specialty and contract pharma shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Alembic Pharmaceuticals Features Among These Oleochemical, Contract Pharma and Generic Stocks

Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Fine Organic Industries vs Anthem Biosciences vs Alembic Pharmaceuticals on Key Financials

The table below sets the three oleochemical, contract pharma and generic stocks side by side on revenue, profit and margin, using reported figures.

Anthem Biosciences posts the highest return on equity in this group at 19.4%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with oleochemical, contract pharma and generic stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Oleochemical, Contract Pharma and Generic Stocks

Every theme carries risks that deserve a check before any decision. For these oleochemical, contract pharma and generic stocks, the main points are: Long-term specialty and contract pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter oleochemical, contract pharma and generic stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Oleochemical, Contract Pharma and Generic Stocks

Oleochemical, contract pharma and generic stocks reward investors who follow demand trends, order books and margins together. Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals each have a clear plan to grow. Based on the 29 October 2026 close, Fine Organic Industries trades at Rs 5,152, Anthem Biosciences at Rs 830.15 and Alembic Pharmaceuticals at Rs 794.85. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these oleochemical, contract pharma and generic stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track oleochemical, contract pharma and generic stocks, set price alerts and get research-backed stock ideas.

What are oleochemical, contract pharma and generic stocks?

Ans. Oleochemical, contract pharma and generic stocks are listed companies that make additives for food, plastics and cosmetics, serve global pharma and biotech firms with discovery, development and manufacturing and sell generics, branded medicines and active ingredients. Their earnings depend on orders, approvals and product mix. This list looks at three of them, Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which oleochemical, contract pharma and generic stocks are covered in this list?

Ans. This list covers Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Based on the 29 October 2026 close, Fine Organic Industries traded at Rs 5,152, Anthem Biosciences at Rs 830.15 and Alembic Pharmaceuticals at Rs 794.85. Their return on equity ranges from 11.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 15.5%.

Why do oleochemical, contract pharma and generic stocks have a strong future roadmap in India?

Ans. Oleochemical, contract pharma and generic stocks have a strong roadmap in India because global drug makers outsourcing more work, wider use of specialty additives and steady medicine demand keep widening the market for these specialty companies. The main drivers are as follows. Outsourcing. Global pharma partners with Indian developers. Specialty additives. Niche products support pricing strength. Generic demand. Medicines bring repeat orders. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Fine Organic Industries performed financially?

Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What risks should investors check before buying oleochemical, contract pharma and generic stocks?

Ans. Investors should check a few risks before buying oleochemical, contract pharma and generic stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of oleochemical, contract pharma and generic stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.